Provided are recombinant Factor VIII proteins, e.g., human Factor VIII proteins, in which one or more amino acids in at least one permissive loops or a3 domain are substituted or deleted, or replaced with heterologous moieties, while retaining the procoagulant activity of Factor VIII.